Introduction:
Myeloid sarcoma (MS), also known as chloroma or granulocytic sarcoma is a condition characterized by abnormal proliferation of blast cells, from one or more myeloid cell, and leads to a disruption in the structure of tissues (1). Its incidence ranges from 2.5% to 8%. It is commonly associated with subtypes of Acute Myeloid Leukemia (AML) such as M5a, M5b, M4 and M2 (2). Myeloid sarcoma can affects various body parts including lymph nodes, skin, soft tissues, testicles, bones, peritoneum and gastrointestinal tract(3,4). It can occur either on its own or as part of an AML relapse. The diagnosis is typically confirmed through immunohistochemistry analysis of a sample taken from the area. Unfortunately the prognosis of myeloid sarcoma is generally poor especially when it is associated with an AML relapse.(5)